Collecting and analyzing biological samples for melanoma treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study aims to implement a comprehensive oncological model focusing on melanoma patients by collecting and biobanking various biological materials, including tissue and liquid biopsies. The study will utilize genomic and epigenomic methods for molecular monitoring to identify new actionable signatures. Patients will be evaluated by a Molecular Tumor Board to facilitate their inclusion in innovative clinical trials. The overarching goal is to enhance existing treatment pathways and establish a robust biostatistical platform for ongoing evaluation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Melanoma affected patients

Exclusion Criteria:

* No patiens affected by other pathology

Where it's running

• Ire
  Roma, Italy Recruiting

Study contacts

• Study coordinator: Patrizio Giacomini, MD
• Email: patrizio.giacomini@ifo.it
• Phone: +39 0652665054

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New method for detecting melanoma biomarkers in blood samples

  This study is testing a new blood test that looks for specific markers of melanoma to see if it works better than current methods.

  Recruiting Regina Elena Cancer Institute · Rome · NCT05940311

• Blood exosomal RNA test to rule out prostate cancer spread to bone

  This project will try a blood-based exosomal RNA test to see if it can rule out bone metastasis in people with newly diagnosed, treatment‑naïve prostate cancer scheduled for baseline PSMA PET.

  Recruiting at 9 sites Xijing Hospital · Lanzhou, Gansu and 8 other locations · NCT07553754

• ctDNA analysis on archived plasma to gauge minimal residual disease in epithelial ovarian cancer

  A single-center study will test whether ctDNA from archived and current blood samples can help identify minimal residual disease in epithelial ovarian cancer patients after surgery.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07546578

• Using urinary tumor DNA to guide how long systemic immunotherapy is given for unresectable very‑high‑risk non‑muscle‑invasive bladder cancer.

  This trial will test whether monitoring urinary tumor DNA lets people with unresectable very‑high‑risk non‑muscle‑invasive bladder cancer stop systemic immunotherapy sooner after they have a complete clinical response.

  Recruiting at 3 sites Phase 2 Tianjin Medical University Second Hospital · Tianjin and 2 other locations · NCT07475403

• Intracranial Venous Blood Sampling for Brain Tumor Liquid Biopsy

  This study tests whether taking blood from veins inside the brain can safely and reliably reveal molecular information about high-grade gliomas using a liquid biopsy.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07467109

• Liquid biopsy testing to identify, monitor, and predict recurrence in urothelial carcinoma

  This project tests whether a multi-component liquid biopsy (blood and urine ctDNA, urine tumor DNA, exosomes, and protein biomarkers) can help detect disease, track treatment response, and predict recurrence in people with suspected or confirmed urothelial carcinoma.

  Recruiting Tianjin Medical University Second Hospital · Tianjin · NCT07441499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.